Error message

Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1445 of /home/patently/domains/xepc.eu/public_html/includes/bootstrap.inc).
Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1445 of /home/patently/domains/xepc.eu/public_html/includes/bootstrap.inc).
Deprecated function: Optional parameter $type declared before required parameter $nid is implicitly treated as a required parameter in include_once() (line 1445 of /home/patently/domains/xepc.eu/public_html/includes/bootstrap.inc).

A.114 EPC Examination by the European Patent Office of its own motion

(1)

In proceedings before it, the European Patent Office shall examine the facts of its own motion; it shall not be restricted in this examination to the facts, evidence and arguments provided by the parties and the relief sought.

(2)

The European Patent Office may disregard facts or evidence which are not submitted in due time by the parties concerned.

See decisions/opinions of the Enlarged Board of Appeal G 7/91, G 8/91, G 9/91, G 10/91, G 4/92, G 9/92, G 8/93, G 10/93, G 1/95, G 7/95, G 1/99 (Annex I).

Source: http://www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar114.html

Date retrieved: 17 May 2021

236 references found. Limiting display to 200 references.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

X Chapter I Common provisions governing procedure

EPC Implementing Rules

X R.116 EPC Preparation of oral proceedings

EPO Guidelines - D Opposition and Limitation/Revocation Procedures

X GL D V 2.2 Examination of the grounds for opposition

X GL D VI 1 General remarks

X GL D VI 3.1 Opposition division's communications

EPO Guidelines - E General Procedural Matters

X GL E III 8.3.3.2 Procedure in opposition proceedings

X GL E III 8.5.1.1 Opposition proceedings ( inter partes )

X GL E III 8.6 Facts, evidence or amendments introduced at a late stage

X GL E III 10.3 Subject-matter of minutes

X GL E VI 1.1 General remarks

X GL E VI 2 Late-filed submissions

X GL E VI 2.1 General examples in opposition proceedings

X GL E VI 2.2 Examples concerning oral proceedings in opposition procedure

X GL E VIII 1.8 Failure to respond within a time limit

Case Law Book: I Patentability

X CLR I C 3.2.4.A General

Case Law Book: III Amendments

X CLR III B 2.1 Violation of the right to be heard examined ex officio

X CLR III B 2.4.5 Failure to consider evidence

X CLR III B 2.6.1 Introduction of a new claim or relevant document

X CLR III C 6.3 Final date for written submissions in the preparation for oral proceedings and late submission of new facts and evidence – Rule 116 EPC

X CLR III C 6.3.2 Appeal proceedings

X CLR III G 3.2 Time frame for submitting evidence

X CLR III H 8 Interpretation of the various language texts of the EPC (Article 177 EPC)

X CLR III J 4.4 Disqualifying partiality

X CLR III N 1 Introduction

X CLR III N 2.4 Anonymously filed observations

X CLR III N 4.2 Introducing a fresh ground for opposition in opposition proceedings

X CLR III N 4.4.1 General

X CLR III R 2.1 Late submission of documents and/or requests

Case Law Book: IV Divisional Applications

X CLR IV C 1 Legal character of opposition proceedings and applicable principles

X CLR IV C 2.1.5 Repeated filing of an opposition by the same person

X CLR IV C 2.2.6 Statement of extent of opposition

X CLR IV C 3.3 Scope of examination of grounds for opposition

X CLR IV C 3.4.1 General

X CLR IV C 3.4.6 Opportunity to comment on new grounds for opposition

X CLR IV C 4.1 Discretionary decision

X CLR IV C 4.2 Sufficient reasoning

X CLR IV C 4.3 Concept of "in due time"

X CLR IV C 4.5.1 Different approaches

X CLR IV C 4.5.2 Review of discretionary decisions by the boards

X CLR IV C 4.7.2 Late submissions of new arguments in opposition proceedings

X CLR IV C 5.1.3 Time frame for filing amendments

X CLR IV C 5.1.4 Amending a non-opposed sub-claim

X CLR IV C 6.2 Invitation to file observations under Article 101(1) EPC

Case Law Book: V Priority

X CLR V A 3.4.1 Boards to examine facts of own motion

X CLR V A 3.4.2 Circumstances where the board need not examine facts of its own motion

X CLR V A 3.5.4 Submissions admitted at first instance are part of the appeal proceedings

X CLR V A 3.5.5 Review of an opposition division's discretionary decision (not) to admit a new ground for opposition

X CLR V A 4.1.1 Legal basis

X CLR V A 4.10.1 New arguments on appeal

X CLR V A 4.10.3 New arguments and lines of attack not admitted

X CLR V A 4.11.1 General principles

X CLR V A 4.11.3.A Not filing documents and evidence at first instance

X CLR V A 4.11.3.C Documents and evidence admitted under Art. 12(4) RPBA 2007

X CLR V A 4.13.1.A General

X CLR V A 4.13.5.B Test reports not admitted into the proceedings

X CLR V A 6.3.1 ‍‍Article 114(1) EPC and withdrawal of the appeal

X CLR V A 9.5.11.C Requests

X CLR V B 3.4.2 Grounds listed exhaustively

Case Law of the Enlarged Board

X G 0007/91 (Withdrawal of appeal) of 5.11.1992

X G 0008/91 (Withdrawal of appeal) of 5.11.1992

X G 0009/91 (Power to examine) of 31.3.1993

X G 0010/91 (Examination of opposition/appeals) of 31.3.1993

X G 0004/92 (Basis of decisions) of 29.10.1993

X G 0009/92 (Non-appealing party) of 14.7.1994

X G 0008/93 (Withdrawal of opposition) of 13.6.1994

X G 0010/93 (Scope of examination in ex parte appeal) of 30.11.1994

X G 0001/95 (Fresh grounds for opposition) of 19.7.1996

X G 0007/95 (Fresh grounds for opposition) of 19.7.1996

X G 0001/99 (Reformatio in peius / 3M) of 2.4.2001

X G 0003/14 () of 24.3.2015

General Case Law

X J 0005/11 () of 6.6.2012

X J 0006/14 (Restitutio in integrum/SIGERGOK) of 2.6.2015

X R 0009/09 () of 22.3.2010

X R 0010/09 () of 22.6.2010

X R 0001/10 (Offensichtlich unzulÃ¤ssiger ÃberprÃ¼fungsantrag/Ahrweiler) of 22.2.2011

X R 0008/11 () of 29.11.2011

X R 0016/13 () of 8.12.2014

X R 0002/14 (Objections to the Chairman and Members of the Enlarged Board of … of 17.2.2015

X R 0006/17 (Petition partially clearly inadmissible and partially clearly … of 28.5.2018

X T 0601/05 (Anti-TNF alpha human monoclonal antibodies/BAYER III) of 2.12.2009

X T 0725/05 (Humanized Immunoglobulins II/PDL) of 14.10.2009

X T 1131/05 () of 19.2.2008

X T 1421/05 () of 18.1.2011

X T 1194/06 (Arylalkylamine carbamates/LABOARATORIOS S.A.L.V.A.T.) of 6.8.2009

X T 0305/07 (Trisulfides/PFIZER) of 20.5.2011

X T 0730/07 (Hydrogenation/ENGELHARD) of 15.4.2010

X T 0897/07 (Abbindebeschleuniger/SIKA Technology AG) of 3.5.2011

X T 1614/07 () of 20.11.2009

X T 1731/07 () of 18.12.2012

X T 2043/07 () of 13.1.2010

X T 0109/08 (Dental Composite/KERR) of 27.1.2012

X T 0295/08 (Skin cleansing composition/COLGATE-PALMOLIVE) of 3.2.2011

X T 0369/08 () of 28.4.2010

X T 0386/08 (Humanized antibodies to the amyloid beta peptide/WASHINGTON … of 22.11.2010

X T 0916/08 () of 6.3.2012

X T 0986/08 () of 13.11.2012

X T 1045/08 () of 10.3.2011

X T 1168/08 () of 10.6.2011

X T 1282/08 (Acariens/STALLERGENES) of 22.6.2011

X T 1440/08 () of 5.8.2010

X T 1545/08 (Combination therapy HCV/MERCK SHARP & DOHME CORP.) of 21.3.2012

X T 1548/08 () of 8.4.2010

X T 1652/08 (Reduktive Aminierung von Carbonylverbindungen/EVONIK DEGUSSA) of 12.4.2011

X T 1675/08 () of 12.10.2010

X T 1698/08 (Taurolidine lock solution/ND PARTNERS) of 28.11.2012

X T 1734/08 () of 14.12.2011

X T 1798/08 () of 21.8.2012

X T 1799/08 () of 18.6.2013

X T 1872/08 (Ink set/SEIKO EPSON) of 20.10.2011

X T 2291/08 () of 8.11.2010

X T 2362/08 () of 14.3.2011

X T 0015/09 () of 19.12.2012

X T 0175/09 () of 18.9.2012

X T 0182/09 (Reinforced foam implants/ETHICON) of 9.2.2012

X T 0406/09 (Cationic cassia derivatives/LUBRIZOL) of 17.11.2010

X T 0443/09 (Process for producing dimethyl ether/TOYO ENGINEERING) of 16.6.2011

X T 0444/09 (Carl Freudenberg/Filtereinsatz) of 26.6.2014

X T 0562/09 () of 30.6.2011

X T 0670/09 (Silylierung von KieselsÃ¤ure/WACKER) of 14.12.2011

X T 0727/09 () of 6.11.2013

X T 1045/09 () of 17.1.2014

X T 1111/09 (Mobile telephone set/KYOCERA) of 22.3.2012

X T 1142/09 () of 10.6.2013

X T 1621/09 () of 22.9.2011

X T 1698/09 () of 10.5.2011

X T 1760/09 () of 22.7.2011

X T 1890/09 () of 26.3.2015

X T 1949/09 () of 26.9.2012

X T 2020/09 () of 5.3.2013

X T 0075/10 (Use of phenethylamine derivatives for treatment of panic disorders/ … of 20.1.2014

X T 0095/10 (UnzulÃ¤ssigkeit der Beschwerde) of 2.8.2011

X T 0111/10 (Diagnosis of spongiform encephalopathy/D-GEN) of 24.6.2014

X T 0217/10 () of 25.3.2015

X T 0245/10 (Composition de teinture/L'OREAL) of 17.10.2012

X T 0317/10 () of 21.1.2014

X T 0657/10 (Stearidonic plant delta desaturases/CALGENE) of 19.12.2013

X T 0973/10 () of 12.7.2011

X T 1100/10 (Detergent Bacillus lentus subtilisin protease egg stains/BASF) of 18.3.2014

X T 1941/10 () of 17.12.2013

X T 2165/10 () of 11.12.2013

X T 2542/10 () of 9.10.2012

X T 0038/11 (Synergistic biocides/SOLENIS TECHNOLOGIES CAYMAN L.P.) of 21.5.2015

X T 0336/11 () of 2.2.2016

X T 0424/11 (BLEICHMITTELKAPSELN/Henkel AG & Co. KGaA) of 19.8.2014

X T 0433/11 (ErkÃ¤ltungskrankheiten/PANDALIS) of 24.5.2012

X T 0531/11 () of 28.11.2014

X T 0605/11 (Cholesterol removal/PRONOVA) of 27.5.2014

X T 0733/11 () of 1.2.2013

X T 0833/11 (Fluticasone furoate/GLAXO) of 8.4.2014

X T 0887/11 () of 5.3.2015

X T 1028/11 () of 5.3.2014

X T 1283/11 () of 15.1.2015

X T 1574/11 () of 19.3.2014

X T 1643/11 () of 3.12.2014

X T 1830/11 () of 29.7.2015

X T 2501/11 (VERKEHRSZEICHENERKENNUNG UND NAVIGATION/BOSCH) of 10.10.2017

X T 2541/11 () of 17.12.2014

X T 0036/12 () of 15.7.2014

X T 0129/12 (Injector deposits control / AFTON) of 29.5.2015

X T 0691/12 () of 21.1.2014

X T 0915/12 () of 25.2.2016

X T 1272/12 () of 11.12.2014

X T 1295/12 () of 28.1.2015

X T 1314/12 (Copolymer fibre/BOREALIS) of 26.2.2014

X T 1364/12 () of 12.2.2015

X T 1581/12 (Outer membrane protein immunogen Neisseria/GLAXOSMITHKLINE) of 15.9.2016

X T 1592/12 (Herceptin dosage regimen/GENENTECH) of 25.10.2016

X T 1763/12 () of 26.11.2015

X T 1847/12 () of 25.1.2017

X T 1883/12 () of 17.11.2014

X T 1933/12 () of 21.2.2014

X T 2219/12 (Sulfur resistant catalyst / BASF) of 3.7.2015

X T 2288/12 () of 6.10.2015

X T 2335/12 (Hydrolysed soy-based medium for producing botulinum toxin/ALLERGAN) of 6.7.2018

X T 2440/12 (Fluid flow simulation/SIMCON) of 15.9.2015

X T 2443/12 () of 6.11.2013

X T 0221/13 () of 28.9.2018

X T 0598/13 () of 14.7.2016

X T 0614/13 (ZulÃ¤ssigkeit des Beitritts/EMS-PATENT) of 2.7.2015

X T 0734/13 () of 15.9.2017

X T 0782/13 (Filterbeutel mit Faservlieslage/EUROFILTERS) of 7.2.2014

X T 0996/13 (Antibody human choline transporter-like protein CTL4 prostate cancer/ … of 6.6.2016

X T 1165/13 () of 26.4.2016

X T 1311/13 (LPS binding peptides/ NATIONAL UNIVERSITY OF SINGAPORE) of 17.1.2018

X T 1528/13 () of 15.12.2017

X T 1589/13 () of 4.10.2017

X T 1654/13 (Dilution-thickening surfactant system / UNILEVER) of 27.1.2015

X T 1819/13 () of 21.2.2018

X T 1820/13 () of 9.2.2018

X T 2393/13 () of 5.2.2016

X T 2415/13 () of 6.10.2015

X T 0039/14 (PropriÃ©tÃ©s moussantes amÃ©liorÃ©es / SEPPIC) of 5.7.2016

X T 0047/14 () of 25.10.2017

X T 0066/14 (Behandlung von biologischen AbfÃ¤llen/FRAUNHOFER-GESELLSCHAFT) of 15.11.2016

X T 0621/14 () of 18.1.2018

X T 0839/14 () of 14.9.2018

X T 0842/14 (PCR anti-foam reagents/QIAGEN) of 23.1.2019

X T 0884/14 () of 15.3.2018

X T 1005/14 (Setting up a medical device/LUNDIA) of 11.8.2016

X T 1404/14 (Graphitised carbon/CATALER) of 20.12.2016